AccScience Publishing / GTM / Volume 2 / Issue 1 / DOI: 10.36922/gtm.v2i1.67
Cite this article
8
Download
10
Citations
61
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW

Inflammatory and anti-inflammatory responses in human T-lymphotropic virus Type 1 infection

Elnaz Sadat Hosseini1 Elham Abdollahi1,2* Nafiseh Saghafi1
Show Less
1 Supporting the Family and the Youth of Population Research Core, Department of Gynecology and Obstrict, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immunology Research Center, Inflammation and Inflammatory Disease Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
Global Translational Medicine 2023 , 2(1), 67; https://doi.org/10.36922/gtm.v2i1.67
Submitted: 14 April 2022 | Accepted: 1 December 2022 | Published: 19 January 2023
© 2023 by the Author(s). Licensee AccScience Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Human T-lymphotropic virus Type 1 (HTLV-1) is a viral infectious agent that may cause chronic infection of T lymphocytes. HTLV-1 infection is related to multiple human diseases, including adult T-cell leukemia, which is a neoplastic growth of HTLV-1-infected T cells, and neoplastic inflammatory conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), Sjögren’s syndrome, polymyositis uveitis, and bronchoalveolitis. T regulatory cells (Tregs), also known as regulatory T cells, and T helper 17 (Th17) cells, a distinct subset of cluster differentiation T cells with interleukin-17 as their major cytokine, orchestrate the pathogenesis of anti-inflammatory and inflammatory responses in HTLV-1-mediated diseases. In this review, we aim to evaluate the immune responses of Tregs as anti-inflammatory cells and Th17 cells as inflammatory cells in HTLV-1 infection.

Keywords
Inflammatory responses
Anti-inflammatory responses
Human T-lymphotropic virus type 1
HTLV-1-associated myelopathy/tropical spastic paraparesis
Funding
None.
References
[1]

Boostani R, Lotfinejad N, Zemorshidi F, et al., 2021, Planning and management to control and eliminate HTLV-1 infection in Iran. Iran J Basic Med Sci, 24: 264–266. https://doi.org/10.22038/ijbms.2021.50803.11562 

[2]

Araya N, Sato T, Yagishita N, et al., 2011, Human T-lymphotropic virus Type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease. Viruses, 3: 1532–1548. https://doi.org/10.3390/v3091532 

[3]

Birmann BM, Breen EC, Stuver S, et al., 2009, Population differences in immune marker profiles associated with human T-lymphotropic virus Type I infection in Japan and Jamaica. Int J Cancer, 124: 614–621. https://doi.org/10.1002/ijc.24012

[4]

Tarokhian H, Rahimi H, Mosavat A, et al., 2018 HTLV- 1-host interactions on the development of adult T cell leukemia/lymphoma: Virus and host gene expressions. BMC Cancer, 18: 1287. https://doi.org/10.1186/s12885-018-5209-5

[5]

Carpentier A, Barez PY, Hamaidia M, et al., 2015, Modes of human T cell leukemia virus Type 1 transmission, replication and persistence. Viruses,7: 3603–3624. https://doi.org/10.3390/v7072793 

[6]

Nagate Y, Ezoe S, Fujita J, et al., 2021, Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia, 35: 107–118. https://doi.org/10.1038/s41375-020-0788-y 

[7]

Higuchi Y, Yasunaga JI, Mitagami Y, et al., 2020, HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proc Natl Acad Sci U S A, 117: 13740–13749. https://doi.org/10.1073/pnas.1922884117

[8]

Koyanagi Y, Itoyama Y, Nakamura N, et al., 1993, In vivo infection of human T-cell leukemia virus Type I in non-T cells. Virology, 196: 25–33. https://doi.org/10.1006/viro.1993.1451

[9]

Overbaugh J, Miller AD, Eiden MV, 2001, Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev, 65: 371–389. https://doi.org/10.1128/MMBR.65.3.371-389.2001

[10]

Jones KS, Fugo K, Petrow-Sadowski C, et al., 2006, Human T-cell leukemia virus Type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol, 80: 8291–8302. https://doi.org/10.1128/JVI.00389-06

[11]

Manel N, Kim FJ, Kinet S, et al., 2003, The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell, 115: 449–459.https://doi.org/10.1016/s0092-8674(03)00881-x 

[12]

Mohammadi S, Abdollahi E, Nezamnia M, et al., 2021, Adoptive transfer of tregs: A novel strategy for cell-based immunotherapy in spontaneous abortion: Lessons from experimental models. Int Immunopharmacol, 90: 107195. https://doi.org/10.1016/j.intimp.2020.107195

[13]

Quaresma JA, Yoshikawa GT, Koyama RV, et al., 2015, HTLV-1, immune response and autoimmunity. Viruses, 8: 5. https://doi.org/10.3390/v8010005

[14]

Lippi G, Lavie CJ, Sanchis-Gomar F, 2020, Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis, 63: 390–391. https://doi.org/10.1016/j.pcad.2020.03.001

[15]

Bhatla A, Mayer MM, Adusumalli S, et al., 2020, COVID-19 and cardiac arrhythmias. Heart Rhythm, 17: 1439–1444. https://doi.org/10.1016/j.hrthm.2020.06.016

[16]

Eggenhuizen PJ, Ng BH, Ooi JD, 2020, Treg enhancing therapies to treat autoimmune diseases. Int J Mol Sci, 21: 7015. https://doi.org/10.3390/ijms21197015

[17]

Christoffersson G, von Herrath M, 2019, Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol, 40: 482–491. https://doi.org/10.1016/j.it.2019.04.005 

[18]

Romano M, Fanelli G, Albany CJ, et al., 2019, Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol, 10: 43. https://doi.org/10.3389/fimmu.2019.00043 

[19]

Bouwman W, Verhaegh W, Holtzer L, et al., 2020, Measurement of cellular immune response to viral infection and vaccination. Front Immunol, 11: 575074. https://doi.org/10.3389/fimmu.2020.575074

[20]

Jin Y, Wi HJ, Choi MH, et al., 2014, Regulation of anti-inflammatory cytokines IL-10 and TGF-β in mouse dendritic cells through treatment with Clonorchis sinensis crude antigen. Exp Mol Med, 46: e74. https://doi.org/10.1038/emm.2013.144

[21]

Sanjabi S, Zenewicz LA, Kamanaka M, et al., 2009, Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol, 9: 447–453. https://doi.org/10.1016/j.coph.2009.04.008 

[22]

Collison LW, Chaturvedi V, Henderson AL, et al., 2010, IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol, 11: 1093–1101. https://doi.org/10.1038/ni.1952 

[23]

Sullivan JA, Tomita Y, Jankowska-Gan E, et al., 2020, Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance. Cell Rep, 30: 1039–1051. e5. https://doi.org/10.1016/j.celrep.2019.12.081

[24]

Shen P, Roch T, Lampropoulou V, et al., 2014, IL-35- producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 507: 366–370. https://doi.org/10.1038/nature12979

[25]

Veldhoen M, Hocking RJ, Atkins CJ, et al., 2006, TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 24: 179–189. https://doi.org/10.1016/j.immuni.2006.01.001

[26]

Konkel JE, Zhang D, Zanvit P, et al., 2017, Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses. Immunity, 46: 660–674. https://doi.org/10.1016/j.immuni.2017.03.015

[27]

Fujimoto Y, Kuramoto N, Yoneyama M, et al., 2020, Interleukin-19 as an immunoregulatory cytokine. Curr Mol Pharmacol, 14: 191–199. https://doi.org/10.2174/1874467213666200424151528

[28]

Abdollahi E, Tavasolian F, Ghasemi N, et al., 2015, Association between lower frequency of R381Q variant (rs11209026) in IL-23 receptor gene and increased risk of recurrent spontaneous abortion (RSA). J Immunotoxicol, 12: 317–321. https://doi.org/10.3109/1547691x.2014.978056

[29]

Castro G, Liu X, Ngo K, et al., 2017, RORγt and RORα signature genes in human Th17 cells. PLoS One, 12: e0181868. https://doi.org/10.1371/journal.pone.0181868

[30]

Park TY, Park SD, Cho JY, et al., 2014, RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells. Proc Natl Acad Sci U S A, 111: 18673–18678. https://doi.org/10.1073/pnas.1413687112

[31]

Chang D, Xing Q, Su Y, et al., 2020, The conserved non-coding sequences CNS6 and CNS9 control cytokine-induced rorc transcription during T helper 17 cell differentiation. Immunity, 53: 614–26. e4. https://doi.org/10.1016/j.immuni.2020.07.012

[32]

Ciofani M, Madar A, Galan C, et al., 2012, A validated regulatory network for Th17 cell specification. Cell, 151: 289–303. https://doi.org/10.1016/j.cell.2012.09.016

[33]

Chi X, Jin W, Zhao X, et al., 2022, RORγt expression in mature TH17 cells safeguards their lineage specification by inhibiting conversion to TH2 cells. Sci Adv, 8: eabn7774. https://doi.org/10.1126/sciadv.abn7774 

[34]

Neco HV, Teixeira VG, Trindade AC, et al., 2017, IL17A polymorphism is not associated with human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis. Viral Immunol, 30: 298–301. https://doi.org/10.1089/vim.2016.0152

[35]

Qu N, Xu M, Mizoguchi I, et al., 2013, Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol, 2013: 968549. https://doi.org/10.1155/2013/968549

[36]

Wolk K, Witte E, Wallace E, et al., 2006, ILcke WD, Kunz S, Asadullah K, et al. cytokines, IL-17, IL-22, and IL-23, ise, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol, 36: 1309–1323. https://doi.org/10.1002/eji.200535503 

[37]

Chang SH, Dong C, 2009, IL-17F: Regulation, signaling and function in inflammation. Cytokine, 46: 7–11. https://doi.org/10.1016/j.cyto.2008.12.024

[38]

Kany S, Vollrath JT, Relja B, 2019, Cytokines in inflammatory disease. Int J Mol Sci, 20: 6008. https://doi.org/10.3390/ijms20236008

[39]

Hirano T, 2021, IL-6 in inflammation, autoimmunity and cancer. Int Immunol, 33: 127–148. https://doi.org/10.1093/intimm/dxaa078

[40]

Martinez NE, Sato F, Kawai E, et al., 2012, Regulatory T cells and Th17 cells in viral infections: Implications for multiple sclerosis and myocarditis. Future Virol, 7: 593–608. https://doi.org/10.2217/fvl.12.44 

[41]

Saghafi N, Rezaee SA, Momtazi-Borojeni AA, et al., 2022, The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19. Life Sci, 294: 120392. https://doi.org/10.1016/j.lfs.2022.120392

[42]

Hamano R, Wu X, Wang Y, et al., 2015, Characterization of MT-2 cells as a human regulatory T cell-like cell line. Cell Mol Immunol, 12: 780–782. https://doi.org/10.1038/cmi.2014.123

[43]

Meissner ME, Mendonça LM, Zhang W, et al., 2017, Polymorphic nature of human T-cell leukemia virus Type 1 particle cores as revealed through characterization of a chronically infected cell line. J Virol, 91: e00369–e00317. https://doi.org/10.1128/jvi.00369-17

[44]

Satou Y, Yasunaga JI, Zhao T, et al., 2011, HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog, 7: e1001274. https://doi.org/10.1371/journal.ppat.1001274

[45]

Kchour G, Rezaee SR, Farid R, et al., 2013, The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology, 10: 91. https://doi.org/10.1186/1742-4690-10-91

[46]

Swaims AY, Khani F, Zhang Y, et al., 2010, Immune activation induces immortalization of HTLV-1 LTR-tax transgenic CD4+ T cells. Blood, 116: 2994–3003. https://doi.org/10.1182/blood-2009-07-231050 

[47]

Champs AP, de Azeredo Passos VM, Carvalho G, et al., 2019, Cognitive impairment in HTLV-1-associated myelopathy, proviral load and inflammatory markers. Int J Infect Dis, 84: 121–126. https://doi.org/10.1016/j.ijid.2019.05.010

[48]

Guo K, Zhang X, 2021, Cytokines that modulate the differentiation of Th17 cells in autoimmune uveitis. J Immunol Res, 2021: 6693542. https://doi.org/10.1155/2021/6693542

[49]

Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, et al., 2016, Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review. J Immunotoxicol, 13: 286–300. https://doi.org/10.3109/1547691x.2015.1115448

[50]

López-Abente J, Correa-Rocha R, Pion M, 2016, Functional mechanisms of treg in the context of HIV infection and the janus face of immune suppression. Front Immunol, 7: 192. https://doi.org/10.3389/fimmu.2016.00192

[51]

Yamano Y, Araya N, Sato T, et al., 2009, Abnormally high levels of virus-infected IFN-γ+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PloS One, 4: e6517. https://doi.org/10.1371/journal.pone.0006517

[52]

Oh U, Grant C, Griffith C, et al., 2006, Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus Type 1 Infection. J Infect Dis, 193: 1557–1566. https://doi.org/10.1086/503874

[53]

Satou Y, Matsuoka M, 2010, HTLV-1 and the host immune system: How the virus disrupts immune regulation, leading to HTLV-1 associated diseases. J Clin Exp Hematop, 50: 1–8. https://doi.org/10.3960/jslrt.50.1

[54]

Toulza F, Heaps A, Tanaka Y, et al., 2008, High frequency of CD4+ FoxP3+ cells in HTLV-1 infection: Inverse correlation with HTLV-1-specific CTL response. Blood, 111: 5047–5053. https://doi.org/10.1182/blood-2007-10-118539

[55]

Brito‐Melo G, Peruhype‐Magalhães V, Teixeira‐Carvalho A, et al., 2007, IL‐10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte‐derived TNF‐α and guarantee asymptomatic clinical status during chronic HTLV‐I infection. Clin Exp Immunol, 147: 35–44. https://doi.org/10.1111/j.1365-2249.2006.03252.x 

[56]

De Sá KS, Santana BB, de Souza Ferreira TC, et al., 2016, IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. Cytokine, 77: 79–87. https://doi.org/10.1016/j.cyto.2015.11.004 

[57]

Sasada A, Takaori-Kondo A, Shirakawa K, et al., 2005, APOBEC3G targets human T-cell leukemia virus Type 1. Retrovirology, 2: 32. https://doi.org/10.1186/1742-4690-2-32

[58]

Best I, López G, Verdonck K, et al., 2009, IFN‐gamma production in response to tax 161-233, and frequency of CD4+ Foxp3+ and Lin-HLA‐DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV‐1‐carriers in a Peruvian population. Immunology, 128(1 Suppl): e777–e86. https://doi.org/10.1111/j.1365-2567.2009.03082.x

[59]

Araújo AQ, Leite AC, Lima MA, et al., 2009, HTLV-1 and neurological conditions: When to suspect and when to order a diagnostic test for HTLV-1 infection? Arq Neuropsiquiatr, 67: 132–138. https://doi.org/10.1590/s0004-282x2009000100036 

[60]

Castro-Costa CM, de Queiroz Campos Araújo A, Câmara CC, et al., 2009, Pain in tropical spastic paraparesis/ HTLV-I associated myelopathy patients. Arq Neuropsiquiatr, 67: 866–870. https://doi.org/10.1590/s0004-282x2009000500016

[61]

Huang Q, Ling Z, Wang H, et al., 2022, Evaluation of the effects of 1, 25VitD3 on Th17 cells and Tregs in HTLV-1 infected cell lines. Acta Virol, 66: 127–138. https://doi.org/10.4149/av_2022_202

[62]

Nakao Y, Koizumi T, Matsui T, et al., 1987, Effect of 1α, 25-dihydroxyvitamin D3 on proliferation of activated T-cells and established human lymphotropic virus Type I-positive T-cell lines. J Natl Cancer Inst, 78: 1079–1086.

[63]

Reichel H, Koeffler HP, Norman AW, 1987, 25-Hydroxyvitamin D3 metabolism by human T-lymphotropic virus-transformed lymphocytes. J Clin Endocrinol Metab, 65: 519–526. https://doi.org/10.1210/jcem-65-3-519

[64]

Koizumi T, Nakao Y, Kawanishi M, et al., 1989, Suppression of c T, Fujita T M, by human T-lymphotropic virus-transformed lymphocytes. hed huma. Int J Cancer, 44: 701–706. https://doi.org/10.1002/ijc.2910440425

[65]

Inoue D, Matsumoto T, Ogata E, et al., 1993, 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, Type I-infected T cells. J Biol Chem, 268: 16730–16736.

[66]

Elstner E, Lee Y, Hashiya M, et al., 1994, 1 alpha, 25-Dihydroxy-20-epi-Vitamin D3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84: 1960–1967. https://doi.org/10.1182/blood.V84.6.1960.1960

[67]

Peter SA, Cervantes JF, 1995, Hypercalcemia associated with adult T-cell leukemia/lymphoma (ATL). J Natl Med Assoc, 87: 746.

[68]

Masutani H, Ueda S, Yodoi J, 2005, The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ, 2: 991–998. https://doi.org/10.1038/sj.cdd.4401625

Conflict of interest
No conflicts of interest.
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021, Print ISSN: TBA, Published by AccScience Publishing